Important note
This AI stock analysis for Resmed is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Resmed - AI Stock Analysis
Analysis generated May 1, 2024
Resmed is a global leader in the development, manufacturing, and marketing of medical equipment for treating, diagnosing, and managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases. It primarily provides innovative products for sleep apnea treatment, including CPAP, Adaptive Servo-Ventilation, and other ventilatory devices. Also, Resmed has diversified into software solutions to streamline patient care and business workflows for healthcare professionals.
Fundamental Analysis
One crucial aspect of fundamental analysis is scrutinizing a company's financial performance. Resmed's revenue for the last quarter was $1.17B, marking a 5.59% increase from the preceding quarter, is a testament to its growth. Year-over-year revenue growth stands at a convincing 12.29%, reinforcing the company's strong market position and expansion. Despite this, net income saw a 4.84% decline quarter-over-quarter, totaling $209M, and a 7.16% decrease from the same quarter last year, raising potential flags about profitability. EBITDA's drop of 4.89% quarter-over-quarter and 1.44% year-over-year to $283M further emphasizes this concern. The current P/E ratio of 33.47 might suggest overvaluation, which, alongside insider stock sales, hints at a possible bearish sentiment within the company.
Technical Analysis
From a technical standpoint, Resmed's stock price exemplifies a healthy upward momentum with a 13.57% increase to $215.01 over the past month. Despite the positive short-term trend, a year-on-year price dip of 7.91% could signal underlying issues. However, the bullish trend is further supported by the current SMA10 of $203.20, higher than the previous SMA10, suggesting ascending price movements. The RSI at 34.2 is in a neutral range, precluding an immediate directional bias.
Alternative Data Analysis
In expanding its workforce by 68%, as noted by the increase in job postings, Resmed appears to be on a growth trajectory. While employee sentiment is neutral, this build-up in human capital could be pivotal for future innovation and expansion. Traffic to the company's website remains constant with 4 million visitors, but tracking customer engagement through social media reveals a different story. A significant 16% increase in Instagram followers to 3,900 may hint at heightened brand awareness and interest. On Twitter, the steady follower count suggests maintained user interest. These elements of alternative data, while not conclusive on their own, nonetheless supplement traditional financial metrics.
Conclusion and Recommendation
Combining the revenue growth with the recent decline in net income and EBITDA, Resmed presents a complex picture. The growing top line is desirable, yet profitability concerns, reflected in the income statements and potential insider bearishness, cannot be overlooked. Technically, the bullish short-term signals raise investor hope but warrant caution considering the longer-term share price decline. The neutral RSI advises against immediate action. In terms of alternative data, the increase in hiring and customer engagement on some social platforms suggests a forward-looking, growing company, but without dramatic changes in web traffic or employee outlook, these indicators serve as mere supplements. Given these mixed signals, a 'Hold' position with a vigilant eye for either further growth evidence or profitability improvements is recommended. Investors should reassess their position if there is a change in fundamental metrics, technical patterns, or alternative data trends.
